Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

PURPOSE: The purpose of this study is to define which visual acuity (VA) measurements are the best indicators of high-quality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD). METHODS: Analysis of prospectively collected data recorded with...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ross, A, Donachie, P, Sallam, A, Stratton, I, Mohamed, Q, Scanlon, P, Kirkpatrick, J, Johnston, R
Format:	Journal article
Idioma:	English
Publicat:	2013

Ítems similars

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
per: Chakravarthy, U, et al.
Publicat: (2012)

Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
per: Sivaprasad, S, et al.
Publicat: (2011)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
per: Rachel Hui Fen Lim, et al.
Publicat: (2017-03-01)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
per: Joachim Wachtlin, et al.
Publicat: (2020-01-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
per: Sun T, et al.
Publicat: (2021-06-01)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
per: Andreas Maunz, PhD, et al.
Publicat: (2023-12-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
per: Zhe-Li Liu, et al.
Publicat: (2013-04-01)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
per: Yi-Sheng Chang, et al.
Publicat: (2018-05-01)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
per: Cvetkova NP, et al.
Publicat: (2016-06-01)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
per: Russo A, et al.
Publicat: (2018-03-01)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
per: Scorcia G, et al.
Publicat: (2010-05-01)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
per: Pongsachareonnont P, et al.
Publicat: (2018-09-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
per: David R. Griffin, et al.
Publicat: (2014-01-01)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
per: Yasuo Yanagi, et al.
Publicat: (2023-05-01)

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
per: Wen-Jie Wang, et al.
Publicat: (2015-02-01)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration.
per: Rishma Gohil, et al.
Publicat: (2015-01-01)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
per: Sarah Sabour-Pickett, et al.
Publicat: (2013-01-01)

Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab.
per: Pearce, E, et al.
Publicat: (2011)

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
per: Menke, Marcel N., et al.
Publicat: (2013)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
per: Gungel H, et al.
Publicat: (2014-05-01)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
per: Yasuo Yanagi, et al.
Publicat: (2023-08-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
per: Francisco Jose Rodriguez, et al.
Publicat: (2019-01-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
per: Sam Razavi, et al.
Publicat: (2021-02-01)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
per: Wang LP, et al.
Publicat: (2018-10-01)

Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey
per: Zafer Cebeci, et al.
Publicat: (2018-02-01)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.
per: Frank G Holz, et al.
Publicat: (2020-01-01)

Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”
per: Dan Călugăru, et al.
Publicat: (2018-11-01)

Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab
per: Cemal Çavdarlı, et al.
Publicat: (2021-04-01)

Role of ranibizumab in management of macular degeneration
per: Singh Rishi, et al.
Publicat: (2007-01-01)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
per: Wataru Matsumiya, et al.
Publicat: (2011-01-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
per: Partha Biswas, et al.
Publicat: (2011-01-01)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
per: Gohil R, et al.
Publicat: (2016-05-01)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
per: Apsangikar P, et al.
Publicat: (2021-07-01)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
per: Veluswamy B, et al.
Publicat: (2020-06-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
per: V. V. Neroev, et al.
Publicat: (2014-07-01)

Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography – case report
per: Martin Pencak, et al.
Publicat: (2021-01-01)

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy
per: Miguel Hage Amaro, et al.
Publicat: (2013-06-01)

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
per: Chakravarthy, U, et al.
Publicat: (2012)

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
per: Chakravarthy, U, et al.
Publicat: (2012)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
per: Juliana Wons, et al.
Publicat: (2017-01-01)